18:01 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy Patient sample and mouse studies suggest agonizing FFAR1 could help treat temporal lobe epilepsy. In postmortem brain tissue samples from patients with temporal lobe epilepsy, neocortical levels of FFAR1 protein were higher than...
18:15 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes In vitro , cell culture and mouse studies identified a pyrrolidine-based FFAR1 agonist that could help treat Type II diabetes. Chemical synthesis and testing in cell-based assays of pyrrolidine analogs identified a compound...
08:00 , Feb 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Bone repair; osteoporosis Free fatty acid receptor 1 (FFAR1; GPR40) Studies in mice suggest GPR40 agonists could help prevent bone...
08:00 , Jan 31, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Free fatty acid receptor 1 (FFAR1; GPR40) In vitro and mouse studies identified an alkyne series of FFAR1 agonists that could help treat...
07:00 , Aug 9, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Free fatty acid receptor 1 (FFAR1; GPR40) Mouse and in vitro studies have identified GPR40 agonists that could help treat type 2 diabetes....
07:00 , Aug 22, 2011 |  BioCentury  |  Product Development

Beta testing GPR40

With concerns about cardiovascular safety and cancer signals dampening optimism about the future of diabetes therapies, there is an emerging race to demonstrate that activating free fatty acid receptor 1 can avoid such safety issues...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Clinical News

Connexios preclinical data

In prediabetic rats, oral CNX-011-67 for 7 weeks significantly enhanced insulin secretion and delayed the onset of fasting glycemia vs. vehicle-treated controls (p<0.01 for both). The free fatty acid receptor 1 ( FFAR1 ; GPR40...